InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

InspireMD amended Series J and K warrants affecting approximately 14.3 million shares, aligning the exercise trigger with anticipated FDA approval of CGuard Prime 80 cm expected in Q4 2026. The amendments could provide up to $11 million in gross proceeds to fund the commercial launch of the TCAR product, which targets an addressable market of over 35,000 annual procedures in the U.S.